

Mammoth Biosciences

Building a Long-Term Biotech Leader

High Science that Delivers – Developing *in vivo* Gene Editing
Therapeutics to Transform Patient Lives

July 2025



Forward Looking Statements



This presentation contains forward-looking statements, which you can identify by terms such as “anticipate,” “believe,” “expect,” “may,” “plan,” “will,” “potential,” “target,” “explore” or other similar expressions. These statements may relate to the potential therapeutic and diagnostic applications of our technology, our ability to advance our internal and partnered pipeline programs, the advantages offered by our ultra compact Cas systems, the initiation, timing and progress of our partnered and internal pre-clinical studies and research and development programs, our future growth, strategies and other matters.


By their nature, these statements are subject to numerous uncertainties and risks, including factors beyond our control, including the uncertainty and risks associated with preclinical studies and research and development programs, or it may take longer or cost more to do so, our ability to obtain additional funding, and our ability to maintain and enforce our intellectual property. These risks and uncertainties cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. Although our management believes that the expectations reflected in our statements are reasonable, recipients are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by laws, we undertake no obligation to update any information or any forward-looking statements as a result of new information, or subsequent events.

Meteoric Rise of CRISPR as a Therapeutic Modality



Since its discovery ~10 years ago, CRISPR is outpacing leading therapeutic modalities based on the rapid increase in preclinical stage assets

Historical Comparison of Preclinical Assets Under Development




There will be breakout companies in each platform

Mammoth’s goal is to be the breakout platform in CRISPR

Sources: Mammoth Biosciences data on file, Citeline Database (figure was adapted). Figures are rounded; CRISPR data includes the following companies which were catalogued internally for competitive intelligence: Arbor Bio, Beam Therapeutics, Caribou Biosciences, Chroma Medicine, CRISPR Therapeutics, Editas Medicine, Epic Bio, Huidagene Therapeutics, Intellia Therapeutics, Life Edit Therapeutics, Mammoth Biosciences, Metagenomi, Prime Medicine, ReCode Therapeutics, Scribe Therapeutics, Tessera Therapeutics, Tome Biosciences, Tune Therapeutics, and Verve Therapeutics.

Despite the advances in gene editing, there are still >5,000 genetic diseases with no available cure



The New York Times

Baby Is Healed With World's First Personalized Gene-Editing Treatment

The technique used on a 9½-month-old boy with a rare condition has the potential to help people with thousands of other uncommon genetic diseases.

The New York Times

Mutated DNA Restored to Normal in Gene Therapy Advance

The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely targeted infusions.

The New York Times

New Gene Editing Treatment Cuts Dangerous Cholesterol in Small Study

The trial involved only 10 patients, but it suggests cholesterol can be permanently reduced with a single treatment for patients at risk of heart disease.

THE WALL STREET JOURNAL


Doctors Can Now Edit the Genes Inside Your Body

It sounds like science fiction, but dozens of people have undergone gene editing for cardiovascular disease and other conditions

Mammoth Unlocks Editing for the Vast Majority of Genetic Diseases



Previously editing technologies have been stuck in tissues such as the blood and liver



Due to Mammoth's compact editors we can go where other editing companies cannot - and tackle the unmet need for most genetic diseases

Source: DeepSeek analysis of OMIM (Online Mendelian Inheritance in Man), Orphanet disease database, NORD, GTEx gene expression data for cross-tissue correlation, and GARD – Genetic and Rare Diseases Information Center, NIH

Translation of CRISPR outpaced RNAi and ASO to IND



~70% reduction in time to value inflection from seminal paper for CRISPR relative to ASOs in the 1970s


Time from Seminal Paper to IND Clearance (In Years)

1977 → 1993

1998 → 2004

2012 → 2017

16



ASO

6



RNAi

5



CRISPR


~69% reduction in time

Path to FDA approval: 11 years vs 20 years for RNAi




Time from seminal paper to FDA approval reduced by nearly half since 1998

Time from Seminal Paper to FDA Approval (In Years)



Sources: [Patterson et al., 1977, FDA](#), [Fire et al., 1998, FDA](#), [Jinek et al., 2012, FDA](#). ASO: antisense oligonucleotide; RNAi: RNA interference.

Gene Therapies have >2x Likelihood of Approval (LOA) vs. Other Modalities from Phase I



	Durable rare disease gene therapy LOA multiple from		
	P1	P1/2; P2	P2/3; P3
Vs. BIO all Tx Areas	2.4x	2.2x	1.3x
Vs. IQVIA all Tx Areas	2.5x	2.1x	1.5x

- Rare disease gene therapies outperform the average drug candidate in all phases of the clinical development process
- NEWDIGS FoCUS Pipeline Analysis Model (PAM) analysis included 597 clinical trials (195 for rare disease gene therapies and 402 for CAR-T and TCR therapies) initiated between 1 January 1988 and 31 December 2023

FDA Continues to Support Rare Diseases and Gene Editing Cures

Comments from June 6, 2025 FDA Cell and Gene Therapy (CGT) Roundtable were constructive

- FDA leadership recently hosted a CGT roundtable with 23 industry experts. Comments were generally supportive with a focus on continuing to support innovation, removing regulatory hurdles and accelerating approvals for rare disease

Vinay Prasad, CBER Director

- Underscored that while **transformational therapies are clearly the goal, incremental improvements are still important**
- FDA will continue to rely on gold standard science and common sense, including **rapid approvals based on surrogate endpoints**, but also monitor overall survival/QOL measures
- Reiterated that **rare, serious disorders cannot have the same review paradigm as prevalent diseases**; willingness to consider the necessity of control arms for certain trials/indications
- **Need for new, innovative therapies for pediatric/rare diseases**
- Interest in **addressing AAV autoimmunity issues through LNPs**
- Emphasized **bringing trials back to the US is a priority**; noted drug development timeframe of 10 years in the US vs. China's goal of four years

Martin Makary, FDA Commissioner

- Plans to continue leveraging priority review and accelerated approval pathways particularly in areas of rare disease where more flexibility is warranted

RFK Jr., HHS Secretary

- Praised recent effort to create a custom gene editing treatment for KJ Muldoon, a baby born with an ultra-rare, life-threatening liver disease
- "...do everything in our power to sweep away the barriers from you getting those solutions to market and getting them funded"

Mehmet Oz, CMS Administrator

- Proclaimed gene therapies were consistent with the Make America Healthy Again movement's "wildest dreams" by offering "true root cause solutions" for disease

Mammoth Highlights



Broad Technology Platform

- Allows disease biology to drive choice of editing modality
- Distinct IP based on ultracompact CRISPR systems



Differentiated Pipeline

- DC selected for MB-111, potential first-in-class *in vivo* gene editing therapeutic for FCS and SHTG*; tracking to 2026 CTA/IND
- Robust extrahepatic editing in NHPs
- Follow-on programs funded by partners



Robust Business Model

- Partnerships:
  
- Ability to opt into equal economics on multiple Regeneron programs

Mammoth is Leading Next-Gen Gene Editing




Significant Accomplishments in 2024

- ✓ Demonstrated robust in vivo liver editing in NHPs with MB-111 (FCS/sHTG)
- ✓ Demonstrated robust extrahepatic editing in a muscle target
- ✓ Achieved proof of concept for editing modalities beyond double stranded breaks
- ✓ Regeneron collaboration with \$100M in upfront/equity and R&D funding for multiple programs across tissues and editing modalities
- ✓ Advanced Bayer and Vertex programs across tissues and editing modalities
- ✓ Strengthened R&D leadership team with key hires (Translational, CMC and beyond)

A Decade of Demonstrated Discovery and Engineering


Early risk-taking led to the discovery and optimization of our breakthrough systems




34 Billion

Proteins

Including exclusive data sources and proprietary analysis approaches




Protein Discovery



Protein Engineering

Mammoth's Ultracompact (<800aa) Systems Solve the Delivery Problem of *in vivo* Gene Editing

 One-third to Half the Size of Legacy Systems




Existing Systems




Mammoth CRISPR Systems Enable All-In-One AAV Delivery To Unlock Targets Beyond the Liver

LNP Delivery




Smaller mRNAs allow for more efficient packaging and improved mRNA quality for delivery *in vivo*

AAV Delivery




Original CRISPR systems
exceed payload restrictions



Mammoth Cas

Leaves abundant room for diverse payloads for precision editing applications



Integrases, Base Editing, CRISPRi/a...

Controlled Expression


Multiplexing

NanoCas Paper and Media Coverage



- Mammoth announced a new study, “Single-AAV CRISPR editing of skeletal muscle in non-human primates with NanoCas, a novel ultracompact nuclease” on Jan 30th
 - Demonstrates how single-AAV CRISPR editing of skeletal muscle in non-human primates could increase the therapeutic potential of gene editing
 - Full paper available on bioRxiv

NanoCas Press Release



NanoCas Paper on BioRxiv



Science Article



GEN Article




Mammoth Ultracompact Systems Enable Nuclease and CRISPR+ Applications



Nuclease

Ultracompact Cas nucleases that cut both strands of target DNA to facilitate a deletion




Nuclease [DNA cleavage]

Ultracompact versions of CRISPR that make double stranded breaks to inactivate genes


CRISPR+

Augmented Cas nucleases with components facilitating precision editing & single-AAV size




EpiCas [methylase]

A platform technology that uses epigenetic modifications to permanently silence genes



OxoCas [deaminase]

A platform technology that makes a single-letter change to convert A to G or C to T



RetroCas [polymerase]

A platform technology that makes versatile RNA-encoded insertions, deletions or substitutions

Mammoth is the Partner of Choice in Next-Gen Gene Editing

Leveraging Financial Capacity of Partners to Fund Broad Pipeline

REGENERON

- Long-term commitment to genetic medicines
- Industry leader with 9 approved products that were internally discovered and developed
- Advanced antibody-directed AAV delivery technology
- Multiple programs across different tissue types and editing modalities with Mammoth



- Pioneer in broad gene editing collaborations with CRISPR Therapeutics in 2015
- Highly experienced in bringing complex drugs to market in record time
- Mammoth recently negotiated rights to control development of an *in vivo* muscle target



- Significant investment and focus in genetic medicine
- Pioneering gene editing work in JV with CRISPR Therapeutics
- Complementary delivery capabilities via AskBio

Transformative Strategic Collaboration Leverages Regeneron's Financial Strength and Drug Development Track Record



REGENERON

Leveraging Mammoth's ultracompact nucleases with Regeneron's commitment to genetic medicines, AAV delivery solutions and successful track record of discovering, developing and commercializing therapies for serious diseases

Mammoth's Leadership in Next-Gen Gene Editing

Genetic Medicines
The future of medicine is now

With a deep history in genetics and technology, Regeneron is expanding its in-house genetic medicines capabilities to empower this growing portfolio. We are leveraging our novel delivery technologies – enabled through our antibodies and viral vectors – with gene editing systems to tackle industry obstacles, and in turn, discover and develop medicines for a wide range of diseases.

LEADERSHIP



Aris Baras, MD
SVP, Co-head of Regeneron Genetic Medicines, Head of Regeneron Genetics Center



Christos Kyratsous, PhD
SVP, Research, Co-head of Regeneron Genetic Medicines



Gary Herman, PhD
SVP, Clinical Development, Unit Head, Genetic Medicines

NOVEL TECHNOLOGY PLATFORMS

Delivery and Payloads
Our distinctive approach of combining novel payload comprehensive ways of attacking difficult-to-treat vectors with enhanced on-target specificity. By its VelociGene®, we can test and validate antibody targets.

Gene Editing
Regeneron is rethinking conventional adeno-asso developing a targeted gene insertion platform, enabling treatment of several disorders where early intervention is critical.

Gene Silencing
Buoyed by our transformative VelociSuite® technology, the forefront of siRNA drug discovery and development and leveraging our industry-leading delivery systems underlying causes of diseases with higher accuracy.

Immunomodulation
Regeneron is investigating strategies for modulating reducing pre-existing antibodies that may exclude antibodies from forming post-dosing to enable re-

DIVERSE RANGE OF DISEASES
Utilizing our expertise and deep understanding of biology allows us to target and expand to disease areas that need more therapeutic options.

- Auditory Diseases
- Cardiovascular & Metabolic Diseases
- Eye Diseases
- Hematologic Diseases
- Lysosomal Storage Disorders
- Musculoskeletal Diseases
- Neurological Diseases

SYNERGISTIC COLLABORATIONS
Collaborating with like-minded companies that share a passion for emerging science and complement our growing genetic medicines portfolio enables us to push boundaries, bringing new medicines to people in need.



Intellia Therapeutics
CRISPR/Cas9-based gene editing focused on liver, central nervous system, muscle, and certain ex vivo products.



Alnylam Pharmaceuticals
Exclusive siRNA collaboration in eye and CNS, with liver programs in NASH and additional RGC targets.



Mammoth Biosciences
Broad access to ultracompact CRISPR gene editing systems.

ADVANCING GENETIC MEDICINES IN THE CLINIC
With deep biology and genetic expertise, and Regeneron Genetics Center® fueling our genetics-based research, we are developing a long-term pipeline that maximizes our home-grown technology platforms.

6
genetic medicines programs in the clinic

20+
additional programs in research and candidate selection phase

20+
novel genetic targets discovered

REGENERON.COM

REGENERON

SYNERGISTIC COLLABORATIONS

Collaborating with like-minded companies that share a passion for emerging science and complement our growing genetic medicines portfolio enables us to push boundaries, bringing new medicines to people in need.



Intellia Therapeutics

CRISPR/Cas9-based gene editing focused on liver, central nervous system, muscle, and certain ex vivo products.



Alnylam Pharmaceuticals

Exclusive siRNA collaboration in eye and CNS, with liver programs in NASH and additional RGC targets.













Mammoth Biosciences

Broad access to ultracompact CRISPR gene editing systems.

"From its foundation, Regeneron has been focused on genetics and how it can influence the way biology is established. At our core, we are trying to explain the way disease and genetics are manifested through different biological pathways so that we may develop genetics-based medicines designed for all."

– Christos Kyratsous,
Co-Head of Regeneron
Genetic Medicines

Mammoth Pipeline of Wholly Owned & Partnered Programs

Indication	Editing Strategy	Status	Research	Optimization	IND Enabling	Initial Addressable US Patients*	Initial Addressable European Patients*
Liver (<i>in vivo</i>)							
FCS/Severe HTG	Double Stranded Break		MB-111 			~40,000	~25,000
Infectious Disease	Gene Silencing	Partnered				~1,000	~1,000 (ROW: ~30,000)
Muscle (<i>in vivo</i>)							
Rare Musculoskeletal Degenerative Disease 1	Reverse Transcriptase	Partnered				~6,000	~10,000
Rare Musculoskeletal Degenerative Disease 2	Undisclosed					~30,000	~30,000
Rare Musculoskeletal Degenerative Disease 3	Gene Silencing	Partnered				~30,000	~30,000
CNS (<i>in vivo</i>)							
Rare Neurodegenerative Disease 1	Undisclosed	Partnered				500-1,000	500-1,000
Rare Neurodegenerative Disease 2	Double Stranded Break, Reverse Transcriptase	Partnered				~15,000	~10,000
Neurological Disorder	Double Stranded Break	Partnered				Ks to Ms, depending	Ks to Ms, depending

*Addressable prevalence estimates leveraged in Mammoth’s 2024 Long Range Plan (LRP) is primarily based on a Headland Strategy Group analysis. Addressable European patient estimates include the UK, Spain, Italy, France, and Germany. CNS: central nervous system; ROW: rest of world.

Proprietary | 20

Significant Progress Driving MB-111 to the Clinic

LNP selection complete, MHRA SciAd complete, CMC & Non clinical activities on track



Non Clinical

- **DC nomination complete in February 2025**
- TPP defined efficacy has been demonstrated in NHPs
- IND-enabling activities well underway, including CMC activities to support non-GLP/GLP tox studies



Regulatory

- **Positive feedback from MHRA in April 2025**
- Positive feedback from FDA INTERACT in Dec 2024
- Pre-CTA (Health Canada) and Pre-IND meetings planned in Q4 2025
- Regulatory Affairs Director, Dr. Jennifer Zeitler, onboarded June 2025



CMC

- **MSAs signed with all key CDMOs**
- Process development work complete for guide & mRNA; LNP process development on-going
- Head of CMC, Dr. Raj Poudel, onboarded June 2025




Clinical

- **VP of Clinical Development, Dr. Sandeep Soni, onboarded May 2025**
- Initiated strategic planning for P1/2 study in 2026
- CRO screening and initiating KOL engagement, identified as 2025 priorities

MB-111: Significant Patient Population with Even Greater Potential beyond Initial Focus



FCS and sHTG with AP history are the priorities; potential to expand into sHTG with high AP risk




MB-111 is a single-dose, *in vivo* gene editing therapy to lower serum triglycerides by targeting APOC3



Gene editing may offer a durable, “one and done” lifelong cure for diseases arising from high TGs

MB-111 as a durable cure for SHTG, PC, and FCS


- APOC3 encodes a small 74 aa lipoprotein that regulates lipid metabolism
- Silencing of APOC3 speeds up catabolism resulting in **reduced triglycerides in serum**
- **MB-111** comprises a CasPhi nuclease mRNA and gRNA encapsulated in a lipid nanoparticle selectively targeting APOC3 in hepatocytes
- APOC3 knock-down (resulting from indels) results in permanent triglyceride lowering




CasPhi LNP Efficiently Forms Indels at APOC3



- Humanized APOC3 mice were dosed with CasPhi and Cas9 LNPs
- **Efficient editing of APOC3 at all doses tested, equivalent to Cas9**




CasPhi LNP Demonstrated Robust APOC3 Protein Knock-down, TG Reduction *in vivo* in a Mouse Model of sHTG





- Human APOC3 knock-in mice (with severely elevated TG) used for MB-111 proof-of-concept studies
- Dosing with LNP results in **95% reduction** in serum triglycerides and **90% reduction** in serum ApoC3 protein

APOC3 Protein




TGs



Ultracompact CasPhi Editing in Liver Comparable to Cas9 in Non-Human Primate (NHP)



- *Interim study with engineered CasPhi*
- CasPhi showed saturating editing at APOC3 and PCSK9 in NHPs - Comparable to larger Cas9
- Minimal editing observed outside of liver
- Test articles well-tolerated in all animals
- Study with final optimized components recently completed




Mammoth's Development Strategy

Progress Beyond Liver



Focus is on expanding skill and asset base to drive forward to high value solutions beyond the liver


Leverage breadth of modalities to find the “best” therapeutic




Lays Platform Foundation for Breakthrough Products



Build sustainable platform safety data to tackle trillion dollar markets over time



Significant Accomplishments and Upcoming Catalysts



Management Team with Deep CRISPR Expertise and Industry Experience



Trevor Martin

CEO, Co-Founder

Stanford
University



Janice Chen

Chief Technology
Officer, Co-Founder

Berkeley
UNIVERSITY OF CALIFORNIA



Lucas Harrington

Chief Scientific
Officer, Co-Founder

Berkeley
UNIVERSITY OF CALIFORNIA



Jennifer Doudna

Chair SAB,
Co-Founder

Berkeley
UNIVERSITY OF CALIFORNIA

hhmi
Howard Hughes
Medical Institute



Elaine Sun

CFO & COO

Halozyme
sutroVax

HARVARD
UNIVERSITY



Gabor Veres

SVP, Translational
Sciences

bluebirdbio®
BIOMARIN Sangamo®
THERAPEUTICS



Siang Chin

General
Counsel

INTUITIVE
SURGICAL®

affymetrix

Supported by top investors and independent board members

RedmileGroup

FORESITE
CAPITAL

德 诚 资 本
DECHENG CAPITAL

NfX

Mayfield

SIXTH
STREET
PARTNERS®

SENATOR

amazon

verily

8VC

Partners

VERTEX



REGENERON

**\$465M+ Capital Raised To Date, including over \$200M from partners
(>\$100M Non-Dilutive Capital)**



A Mammoth Opportunity

**High Science that Delivers –
Developing *in vivo* Gene Editing
Therapeutics to Transform Patient Lives**

Ultracompact CRISPR Platform

to solve the delivery problem of in vivo gene editing and address safety concerns

Pipeline Across Tissue Types & Modalities

Lead Candidate in FCS, PC and sHTG, and going beyond liver targets into new editing modalities

Long-Term Company Building

with high science, credible partner validation, strong financial position, distinct IP estate, and a Mammoth opportunity to address unmet patient need




Additional Key Team Members

Seasoned Translational, Clin. Development and TechOps Leads with Proven Track Records in Genetic Medicines



Gabor Veres, PhD
SVP Translational Sciences

- PhD in Genetics and Biochemistry
- Previously Chief Scientific Officer at Vedere Bio and Vice President and Head of Genetic Therapy Research at **BioMarin** focusing on AAV platform discovery and identifying new therapeutic indications in gene therapy
- **bluebird bio**: Vice President of Preclinical Research, where he initiated and coordinated numerous research programs aimed at viral gene delivery to treat genetic and acquired diseases
- Successfully led several projects from preclinical research to clinical development, including ZYNTEGLO® and SKYSONA®



Sandeep Soni, MD
VP Clinical Development

- Trained MD in pediatric hematology/oncology/stem cell transplant
- Stem Cell Transplants for hemoglobinopathies in academia
- **bluebird bio**: Phase 1-2 for Thalassemia and SCD (ZYNTEGLO®, LYFENGIA®)
- **CRISPR Therapeutics**: Phase 1-2 studies CRISPR gene editing of BCL11a for thalassemia and SCD (CASGEVY®)
- IND/CTA clearances and Phase 1 study of CRISPR gene-edited embryonic stem cells matured to pancreatic endodermal cells for T1 Diabetes
- IND/CTA clearances and Phase 1 studies of CRISPR gene editing of ANGPTL3 and LPa for hyperlipidemias



Aruna Perera, PhD
VP Technical Operations

- PhD in Organic Chemistry and Biochemistry
- **Ultragenyx**: Led CMC/AD/QC activities for proteins and gene therapy
- Previously Head of CMC at Carmot Therapeutics, Head of CMC at Biora Therapeutics and CMC Team leader at Bausch Health Companies
- Lead 9 INDs in various modalities and supported 2 BLAs and 2 NDAs
- Extensive CMC experience across modalities from early development to commercialization

Additional Clinical and Regulatory Team Members



Wing-Yen Wong, MD
CMO Consultant

- Played pivotal roles in the development and approval of various therapies including the first gene therapy for Hemophilia A (Roctavian), FEIBA, Advate, Adynovate, Eloctate, Alprolix, Rixubis, Obizur, and the first recombinant von Willebrand factor (Vonvendi)
- Previously Group Vice President of Global Medical Affairs and Scientific Strategy at BioMarin and led the development and approval of Roctavian for Hemophilia A. Provided groundbreaking leadership in the design and oversight of over six years of the AAV5 clinical trials reported in NEJM publications including the largest Phase 3 clinical trial in gene therapy for Hemophilia to date
- Prior to BioMarin, Dr. Wong was Vice President of Global Medical and Head of Clinical Research of Hemophilia at Biogen and Baxter respectively



Jennifer Zeitler, PhD
Director, Regulatory Affairs

- PhD in Molecular and Cell Biology
- Previously Associate Director of Regulatory Affairs at Dren Bio, Senior Manager of Regulatory Affairs and Scientist at Sangamo Therapeutics
- Expansive understanding of the development of gene editing, gene therapy, cell therapy, and antibody therapeutic products
- Substantial experience in metabolic, central nervous system, autoimmune, hematologic, and oncologic indications, including rare diseases
- Provided Regulatory Leadership on many early and mid-stage clinical trial programs, and successfully supported teams to gain alignment on registrational clinical trial design from both CBER and CDER at FDA



Mike Murtagh
Regulatory Consultant

- More than 20 years of experience leading global regulatory strategies across all phases of development, as well as multiple disease areas and therapeutic modalities
- Currently Senior Vice President of Regulatory Affairs at AAVantgarde; previously served as Senior Vice President, Regulatory Affairs at Vedere Bio II and Vice President, Regulatory Affairs at Astellas Gene Therapies (formerly Audentes Therapeutics) and before that at BioMarin with increasing levels of regulatory responsibilities